- Company Recognized for Continued Superior Energy Achievements -
DUBLIN, April 9, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced it will release first quarter 2019 financial results on Tuesday, May 7, 2019, prior to the open of U.
Digital Boom and Millennials are Growing the Category, Wellness and Self-Care are New Key Drivers, Interest is in Eyes and Body Contouring
Digital Boom and Millennials are Growing the Category, Wellness and Self-Care are New Key Drivers, Interest is in Eyes and Body Contouring
Today, Aegon N.V.
The MAPLE study used a modified manufacturing process and demonstrated decreased intraocular inflammation
Today, Aegon successfully priced its inaugural EUR 500 million Restricted Tier 1 perpetual contingent convertible securities, with a fixed coupon of 5.
There's been enough news with the lawsuits around this name to get the emotion back into the stock. Emotion often leads to volatility.
- Proprietary Skin Resurfacing Treatment for the Face and Body Reinforces Allergan's Commitment to Skin Quality -
Today, Aegon N.V.
-- Television Personality is Spokesperson for the World's #1 Nonsurgical Fat Reduction Treatment* --
- Label Now Includes New Data on Use of AVYCAZ for Treatment of cUTI and cIAI in Pediatric Patients 3 Months of Age and Older -
- New data to address the treatment duration potential of first-in-class sustained release biodegradable implant -
In this day and age, companies must be 'disruptors' or get left in the dust.
- Ubrogepant Seeks to be the First Oral Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist for the Acute Treatment of Migraine -
With shares breaking above the recent, albeit small, pennant, there might be reason for optimism.
Jim Cramer's watching six stocks to determine when the selling will end.
Allergan is another stock that could stay stuck in its Doldrums. See which of its peers Jim Cramer likes better and why.
David Tepper's Appaloosa LP renews calls for changes at the top.
Allergan wants Botox licenses for pediatric patients.
Applications Seek to Extend Use of BOTOX® for Patients 2 to 17 Years Old
The approval of esketamine, known as Spravato, for use against severe depression is special -- it is saving lives.
-- Three acute pivotal studies did not meet their primary endpoint --
DUBLIN, March 4, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global biopharmaceutical company, today announced that Chief Financial Officer Matthew Walsh will participate in a fireside chat at the Cowen and Company 39 th Annual Health Care...
DUBLIN, March 1, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that its data will be featured during the 2019 American Academy of Dermatology (AAD) Annual Meeting in Washington D.
DUBLIN, Feb. 19, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today issued the following statement from its Board of Directors in response to a public shareholder letter: "While we appreciate the input of Appaloosa as we do all of our shareholders, we...
- Sixth New Director Since 2017 as Part of Allergan's Transformation from a Generic to a Branded Biopharmaceutical Company -
ClaimsFiler, a FREE shareholder information service, reminds investors that they have only until February 19, 2019 to file lead plaintiff applications in a securities class action lawsuit against Allergan plc.
